R-Pharm

rpharm.ru

Matched: R-Pharm International, LLC · R-Pharm · R-Pharm Overseas, Inc.

Live pipeline data from ClinicalTrials.gov, refreshed daily.

Total trials

77

Active

11

Phase 3

27

Total enrollment

18,439

Pipeline matrix

Showing 23 of 23 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
RPH-104———7
Olokizumab———7
Docetaxel———4
Trastuzumab————2
Subcutaneous—————1
SC injections of Placebo every 4 weeks (q4w), one injection of 0.4 mL—————1
RPH-051—————1
Perjeta®—————1
Goflikicept—————1
OKZ q4w—————1
RS-113, 160 mg—————1
RS-113, 240 mg—————1
RS-113, 320 mg—————1
Abiraterone—————1
Prednisolone—————1
Androgen deprivation therapy—————1
RPH-035—————1
Ocrevus®—————1
RPH-030—————1
Vectibix®—————1
Irinotecan—————1
Calcium Folinate—————1
Fluorouracil—————1

Next readouts

  • 2025-01
  • 2025-10-15
  • 2026-01
  • 2026-04-10
  • 2026-05-14
  • 2026-05-15
  • 2026-06-02
  • 2026-09
  • 2027-04-09
  • 2027-12-14

Top conditions

  • Metastatic Breast Cancer8
  • COVID-198
  • Breast Cancer5
  • Rheumatoid Arthritis5
  • Healthy4
  • Cancer3
  • Advanced Solid Tumors3
  • Head and Neck Squamous Cell Carcinoma3

Frequently asked questions about R-Pharm

How many clinical trials does R-Pharm have on ClinicalTrials.gov?
R-Pharm is listed as the lead sponsor on 77 clinical trials in ClinicalTrials.gov, 11 of which are currently active (recruiting, enrolling, or ongoing).
How many of R-Pharm's trials are in Phase 3?
27 of R-Pharm's trials are in Phase 3, spread across 23 active drug programs.
What therapeutic areas does R-Pharm focus on?
R-Pharm's most-studied conditions on ClinicalTrials.gov are Metastatic Breast Cancer, COVID-19, Breast Cancer, Rheumatoid Arthritis, Healthy.
When are R-Pharm's next clinical trial readouts?
R-Pharm has 10 upcoming primary-completion readouts tracked here; the soonest is “Efficacy and Safety of RPH-104 for Resolution and Prevention of Recurring Attacks in Adult Subjects With Familial Mediterranean Fever With Resistance to or Intolerance of Colchicine”, expected around 2025-01.